Z11.1

Clinical Causes: Exposure to contagious individuals with active TB disease Living in or traveling to regions with high TB prevalence Immunocompromising conditions such as HIV/AIDS, diabetes, or malnutrition Close contact with people diagnosed with active TB History of incarceration or homelessness Use of certain medications that weaken the immune system

Key Symptoms: Typically, individuals undergoing screening do not have symptoms Possible mild symptoms if latent TB progresses to active disease, such as: Persistent cough lasting more than three weeks Chest pain or discomfort Coughing up blood or sputum Unintentional weight loss Fever or night sweats Fatigue or weakness Loss of appetite

Diagnosis Path: Tuberculin Skin Test (TST): also known as the Mantoux test, where a small amount of purified protein derivative (PPD) is injected under the skin, and the skin’s reaction is measured after 48-72 hours. Interferon-Gamma Release Assays (IGRAs): blood tests that detect immune responses to TB bacteria, with results available in a few days. Chest X-ray: used to identify any lung abnormalities suggestive of active TB. Sputum Analysis: for individuals with symptoms or abnormal chest X-ray findings, sputum samples are examined for TB bacteria. Additional tests may include molecular assays to rapidly detect TB DNA and drug resistance.

Treatment Protocols: Latent TB infection treatment with medications such as isoniazid, rifampin, or a combination therapy over several months. Monitoring and follow-up to ensure completion of therapy and prevent progression to active disease. Prompt treatment of active TB with multi-drug regimens to eradicate bacteria and prevent transmission. Infection control measures, such as isolation procedures when active TB is suspected or confirmed. Preventative counseling and education on reducing exposure and improving health status.